Oric Pharmaceuticals, Inc. (ORIC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective July 28, 2026, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the OR
How this was made
The 30-second read
Why it matters
The provided text mainly reproduces inducement equity plan terms and does not include the concrete leadership changes or award economics needed to forecast earnings or cash-flow impacts.
Market read
Primarily governance and compensation documentation; tradable impact depends on the specific individuals and award terms not included in the excerpt.
What to watch
Traders should verify whether the filing includes specific grant sizes, vesting terms, or employment inducement triggers that could affect dilution expectations.
Background
The filing is an SEC Form 8-K under Item 5.02, which typically reports leadership changes and related compensatory arrangements.
Ticker impact
Oric Pharmaceuticals filed an 8-K Item 5.02 covering director/officer departures, elections, and compensatory arrangements tied to its inducement equity plan.
Likely limited near-term impact unless the filing specifies material leadership changes or unusually large equity grants (not shown in the provided excerpt).
The excerpt confirms the 8-K item and includes the inducement equity plan language, but does not provide the specific individuals, terms, or grant sizes that would drive a tradable repricing.
Market effects
Routine equity-compensation and board/officer updates for a biotech issuer, with no disclosed sector-wide regulatory or clinical signal in the excerpt.
None indicated.
None indicated.
Counterpoint
If the omitted portions of Item 5.02 include a sudden executive departure or a major new appointment, the market reaction could be larger than typical compensation-plan boilerplate.
Key entities
- issuerOric Pharmaceuticals, Inc.
Subject of the SEC 8-K Item 5.02 disclosure covering director/officer changes and compensatory arrangements.
